Ricerca
Didattica
Soluzioni
Accedi
IT
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Qi-Xang Li has not added Biography.
If you are Qi-Xang Li and would like to personalize this page please email our Author Liaison for assistance.
Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Bioorganic & medicinal chemistry letters Jun, 2015 | Pubmed ID: 26130408
Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Bioorganic & medicinal chemistry letters Apr, 2016 | Pubmed ID: 26979157
Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines.
Cancer research 08, 2016 | Pubmed ID: 27325646
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Molecular cancer therapeutics 04, 2017 | Pubmed ID: 27903750
Experimental animal modeling for immuno-oncology.
Pharmacology & therapeutics May, 2017 | Pubmed ID: 28167217
EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.
Oncology reports Oct, 2017 | Pubmed ID: 28849161
Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Molecular medicine reports Apr, 2018 | Pubmed ID: 29484394
Crown Bioscience Inc.
Peking University
Xiaoyu An*,1,2,
Xuesong Ouyang*,1,
Hui Zhang1,
Tingting Li1,
Yu-yang Huang1,
Zhiyuan Li1,
Demin Zhou2,
Qi-Xang Li1,2
1, Crown Bioscience Inc.,
2State Key Laboratory of Natural and Biomimetic Drugs, Peking University
Riservatezza
Condizioni di utilizzo
Politiche
Contattaci
SUGGERISCI JOVE ALLA BIBLIOTECA
Newsletter di JoVE
JoVE Journal
Raccolta di metodi
JoVE Encyclopedia of Experiments
Archivio
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Sportello unico per docenti
Autori
Personale delle biblioteche
Accesso
CHI SIAMO
Copyright © 2024 MyJoVE Corporation. Tutti i diritti riservati